Literature DB >> 24699434

Riproximin is a recently discovered type II ribosome inactivating protein with potential for treating cancer.

Hassan Adwan1, Helene Bayer1, Asim Pervaiz1, Micah Sagini1, Martin R Berger2.   

Abstract

The development of new anticancer drugs is a salient problem and the traditional use of plants is a potentially rich source of information for detecting new molecules with antineoplastic activity. Riproximin is a recently detected cytotoxic type II ribosome inactivating protein with high selectivity for certain tumor cell lines. Its activity was recognized as the main component in a plant powder used by African healers for treating cancer. By ribulose bisphosphate carboxylase gene sequencing analysis, the powder was identified to be derived from the plant Ximenia americana. The cDNA sequence of riproximin was identified, the protein was modeled to contain one A- and a B-chain, respectively, and a reliable purification procedure from kernels of X. americana was established. Riproximin displays high but differential antiproliferative activity in a panel of human and rodent cancer cell lines, with concentrations inhibiting cell proliferation by 50% (IC50 values) that diverge by a factor of 100. Consistent antineoplastic activity was detected in colorectal and pancreatic cancer liver metastasis models in rats. The cytotoxic mechanism of action was determined to be based on cellular uptake of riproximin followed by its A-chain prompted depurination of the 28S ribosomal RNA and induction of unfolded protein response. Riproximin's specificity depended on its B-chain connected binding to cell surface glycans, the presence of which is crucial for subsequent internalization into cells and cytotoxicity. These N- and O-glycans include bi- and tri-antennary NA structures (NA2/NA3) as well as Tn3 structures (clustered Tn antigen). Riproximin was found to crosslink proteins with N- and O-glycan structure, thus indicating both types of binding sites on its B chain. Due to this crosslinking ability, riproximin is expected to show prominent cytotoxicity towards cells expressing both, NA2/NA3 and clustered Tn structures. Apart from the properties of riproximin, the plant X. americana has been known for some medical uses in traditional African medicine, including various types of infections.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antineoplastic activity; Lectin; Ribosome inactivating protein type II; Riproximin; Unfolded protein response; Ximenia americana

Mesh:

Substances:

Year:  2014        PMID: 24699434     DOI: 10.1016/j.biotechadv.2014.03.008

Source DB:  PubMed          Journal:  Biotechnol Adv        ISSN: 0734-9750            Impact factor:   14.227


  9 in total

1.  Riproximin modulates multiple signaling cascades leading to cytostatic and apoptotic effects in human breast cancer cells.

Authors:  Asim Pervaiz; Michael Zepp; Hassan Adwan; Martin R Berger
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-12       Impact factor: 4.553

2.  Expression profiling of anticancer genes in colorectal cancer patients and their in vitro induction by riproximin, a ribosomal inactivating plant protein.

Authors:  Asim Pervaiz; Talha Saleem; Kinzah Kanwal; Syed Mohsin Raza; Sana Iqbal; Michael Zepp; Rania B Georges; Martin R Berger
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-17       Impact factor: 4.322

3.  Winter Aconite (Eranthis hyemalis) Lectin as a cytotoxic effector in the lifecycle of Caenorhabditis elegans.

Authors:  Marie-Therese McConnell; David R Lisgarten; Lee J Byrne; Simon C Harvey; Emilia Bertolo
Journal:  PeerJ       Date:  2015-08-20       Impact factor: 2.984

Review 4.  Anti-tumor activities and apoptotic mechanism of ribosome-inactivating proteins.

Authors:  Meiqi Zeng; Manyin Zheng; Desheng Lu; Jun Wang; Wenqi Jiang; Ou Sha
Journal:  Chin J Cancer       Date:  2015-07-17

Review 5.  Plant Lectins Targeting O-Glycans at the Cell Surface as Tools for Cancer Diagnosis, Prognosis and Therapy.

Authors:  Guillaume Poiroux; Annick Barre; Els J M van Damme; Hervé Benoist; Pierre Rougé
Journal:  Int J Mol Sci       Date:  2017-06-09       Impact factor: 5.923

Review 6.  New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets.

Authors:  Pooneh Mokarram; Mohammed Albokashy; Maryam Zarghooni; Mohammad Amin Moosavi; Zahra Sepehri; Qi Min Chen; Andrzej Hudecki; Aliyeh Sargazi; Javad Alizadeh; Adel Rezaei Moghadam; Mohammad Hashemi; Hesam Movassagh; Thomas Klonisch; Ali Akbar Owji; Marek J Łos; Saeid Ghavami
Journal:  Autophagy       Date:  2017-02-23       Impact factor: 16.016

7.  Riproximin Exhibits Diversity in Sugar Binding, and Modulates some Metastasis-Related Proteins with Lectin like Properties in Pancreatic Ductal Adenocarcinoma.

Authors:  Micah N Sagini; Karel D Klika; Andrew Orry; Michael Zepp; Joshua Mutiso; Martin R Berger
Journal:  Front Pharmacol       Date:  2020-11-30       Impact factor: 5.810

8.  Zanthoxylum heitzii Modulates Ferric Nitrilotriacetate-Dependent Oxidative Alterations in Four Vital Organs: An In Vitro Organoprotective Model.

Authors:  Jacques Joël Essogo; Bruno Moukette Moukette; Francine Nzufo Tankeu; Pauline Nanfack; Constant Anatole Pieme
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-09       Impact factor: 2.629

9.  Synthesis of Gold Functionalised Nanoparticles with the Eranthis hyemalis Lectin and Preliminary Toxicological Studies on Caenorhabditis elegans.

Authors:  Jamila Djafari; Marie T McConnell; Hugo M Santos; José Luis Capelo; Emilia Bertolo; Simon C Harvey; Carlos Lodeiro; Javier Fernández-Lodeiro
Journal:  Materials (Basel)       Date:  2018-08-06       Impact factor: 3.623

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.